190 276

Cited 29 times in

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

 J. J. Knox  ;  C. H. Barrios  ;  T. M. Kim  ;  T. Cosgriff  ;  V. Srimuninnimit  ;  K. Pittman  ;  R. Sabbatini  ;  S. Y. Rha  ;  T. W. Flaig  ;  R. D. Page  ;  J. T. Beck  ;  F. Cheung  ;  S. Yadav  ;  P. Patel  ;  L. Geoffrois  ;  J. Niolat  ;  N. Berkowitz  ;  M. Marker  ;  D. Chen  ;  R. J. Motzer 
 ANNALS OF ONCOLOGY, Vol.28(6) : 1339-1345, 2017 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Renal Cell/drug therapy* ; Cross-Over Studies ; Everolimus/administration & dosage ; Female ; Humans ; Indoles/administration & dosage ; Kidney Neoplasms/drug therapy* ; Male ; Middle Aged ; Prognosis ; Pyrroles/administration & dosage ; Survival Analysis ; Young Adult
everolimus ; renal cell carcinoma ; sequential targeted therapy ; sunitinib
Background: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.

Patients and methods: Patients received either first-line everolimus followed by second-line sunitinib at progression (n = 238) or first-line sunitinib followed by second-line everolimus (n = 233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored.

Results: At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1-26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0-29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9-1.6]. Median OS was 22.4 months (95% CI 18.6-33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8-33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1; 95% CI 0.9-1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences.

Conclusions: Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals.

Clinical Trials number: ClinicalTrials.gov identifier, NCT00903175.
Files in This Item:
T201703713.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.